MA44253A - Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m1 - Google Patents

Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m1

Info

Publication number
MA44253A
MA44253A MA044253A MA44253A MA44253A MA 44253 A MA44253 A MA 44253A MA 044253 A MA044253 A MA 044253A MA 44253 A MA44253 A MA 44253A MA 44253 A MA44253 A MA 44253A
Authority
MA
Morocco
Prior art keywords
acetylcholin
muscarinic
receptor
positive allosteric
allosteric modulators
Prior art date
Application number
MA044253A
Other languages
English (en)
Inventor
Katrina A Bollinger
P Jeffrey Conn
Darren W Engers
Julie L Engers
Craig W Lindsley
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of MA44253A publication Critical patent/MA44253A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA044253A 2016-02-16 2017-02-16 Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m1 MA44253A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662296012P 2016-02-16 2016-02-16
US201662402438P 2016-09-30 2016-09-30

Publications (1)

Publication Number Publication Date
MA44253A true MA44253A (fr) 2018-12-26

Family

ID=59626207

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044253A MA44253A (fr) 2016-02-16 2017-02-16 Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m1

Country Status (15)

Country Link
US (1) US11111251B2 (fr)
EP (1) EP3416639B1 (fr)
JP (1) JP2019504901A (fr)
KR (1) KR20180110132A (fr)
CN (1) CN109069491A (fr)
AU (1) AU2017221404A1 (fr)
BR (1) BR112018016689A2 (fr)
CA (1) CA3014791A1 (fr)
CL (1) CL2018002335A1 (fr)
EA (1) EA201891854A1 (fr)
IL (1) IL261058A (fr)
MA (1) MA44253A (fr)
MX (1) MX2018009952A (fr)
PH (1) PH12018501731A1 (fr)
WO (1) WO2017143041A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019002180A (es) * 2016-09-02 2019-08-16 Suven Life Sciences Ltd Moduladores alostericos positivos del receptor m1 muscarinico.
EA035599B1 (ru) * 2017-04-13 2020-07-14 Сувен Лайф Сайенсиз Лимитед Позитивные аллостерические модуляторы мускариновых m1-рецепторов
WO2018235838A1 (fr) * 2017-06-20 2018-12-27 武田薬品工業株式会社 Composé hétérocyclique
EP3643718B1 (fr) * 2017-06-20 2023-07-26 Takeda Pharmaceutical Company Limited Composé hétérocyclique et son utilisation comme modulateur allostérique positif du récepteur muscarinique cholinérgique m1
CN111491920B (zh) 2017-10-20 2024-01-30 范德比尔特大学 毒蕈碱性乙酰胆碱受体m4的拮抗剂
AU2018354969B2 (en) 2017-10-27 2020-09-17 Suven Life Sciences Limited Polycyclic amides as muscarinic M1 receptor positive allosteric modulators
CN111565718A (zh) 2017-10-31 2020-08-21 范德比尔特大学 毒蕈碱性乙酰胆碱受体m4的拮抗剂
JP7352294B2 (ja) 2018-02-02 2023-09-28 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
WO2019241467A1 (fr) * 2018-06-13 2019-12-19 Vanderbilt University Modulateurs allostériques positifs du récepteur m1 de l'acétylcholine muscarinique
EP3858828A4 (fr) 2018-09-28 2022-07-06 Takeda Pharmaceutical Company Limited Composé hétérocyclique
EP3858823A4 (fr) 2018-09-28 2022-07-06 Takeda Pharmaceutical Company Limited Composé cyclique condensé
EP3643711A1 (fr) * 2018-10-24 2020-04-29 Bayer Animal Health GmbH Nouveaux composés anthelminthiques
WO2020086864A1 (fr) 2018-10-24 2020-04-30 Vanderbilt University Modulateurs allostériques positifs du récepteur d'acétylcholine muscarinique m1
US20240083907A1 (en) * 2019-10-04 2024-03-14 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608079A (en) 1983-08-02 1986-08-26 American Cyanamid Company Imidazolidinones, and imidazolidinethiones, process and intermediates for the preparation thereof, and use of said compounds as herbicidal agents
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
EP1159279B1 (fr) 1999-03-09 2002-10-16 PHARMACIA & UPJOHN COMPANY AGENTS ANTIVIRAUX DE 4-OXO-4,7-DIHYDRO-THIENO 2,3-b]PYRIDINE-5-CARBOXAMIDES
CN101016296A (zh) * 2000-04-28 2007-08-15 阿卡蒂亚药品公司 毒蕈碱性激动剂
IL160884A0 (en) * 2001-10-02 2004-08-31 Upjohn Co Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
JP5651708B2 (ja) * 2009-12-17 2015-01-14 メルク・シャープ・エンド・ドーム・コーポレイション キノリンアミド化合物ｍ１受容体陽性アロステリックモデュレータ
US8815902B2 (en) 2010-06-15 2014-08-26 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide M1 receptor positive allosteric modulators
WO2012158474A1 (fr) * 2011-05-17 2012-11-22 Merck Sharp & Dohme Corp. Modulateurs allostériques positifs du récepteur m1 au quinoline-amide à liaison n
US20160200733A1 (en) 2013-08-23 2016-07-14 Vanderbilt University Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
TW201512197A (zh) * 2013-08-30 2015-04-01 Hoffmann La Roche 吡咯并吡啶或吡唑并吡啶衍生物
GB201317363D0 (en) * 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
CA2930961A1 (fr) 2014-01-22 2015-07-30 F. Hoffmann-La Roche Ag Derives de fluoro-naphtyle
EP3156397B1 (fr) 2014-06-13 2019-08-07 Takeda Pharmaceutical Company Limited Composé hétérocyclique contenant de l'azote
WO2016009297A1 (fr) * 2014-07-18 2016-01-21 Pfizer Inc. Dérivés de la pyridine en tant que modulateurs allostériques positifs du récepteur m1 muscarinique
WO2016029454A1 (fr) 2014-08-29 2016-03-03 Merck Sharp & Dohme Corp. Dérivés de tétrahydronaphtyridine comme modulateurs allostériques négatifs de mglur2, compositions et leur utilisation
MX2019002180A (es) 2016-09-02 2019-08-16 Suven Life Sciences Ltd Moduladores alostericos positivos del receptor m1 muscarinico.

Also Published As

Publication number Publication date
EP3416639A4 (fr) 2019-07-03
WO2017143041A1 (fr) 2017-08-24
AU2017221404A1 (en) 2018-08-23
EP3416639A1 (fr) 2018-12-26
PH12018501731A1 (en) 2019-06-17
KR20180110132A (ko) 2018-10-08
US11111251B2 (en) 2021-09-07
EA201891854A1 (ru) 2019-01-31
JP2019504901A (ja) 2019-02-21
CA3014791A1 (fr) 2017-08-24
IL261058A (en) 2018-10-31
EP3416639B1 (fr) 2022-06-08
MX2018009952A (es) 2018-11-29
BR112018016689A2 (pt) 2019-02-12
CN109069491A (zh) 2018-12-21
CL2018002335A1 (es) 2019-02-01
US20210230180A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
MA44253A (fr) Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m1
MA45463A (fr) Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
IL264951B (en) Positive allosteric modulators of the m1 muscarinic receptor
DK3452448T3 (da) Modulatorer af den integrerede stressvej
MA43756A (fr) Modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine
MA46722A (fr) Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4
MA47126A (fr) Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4
MA47127A (fr) Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
MA46899A (fr) Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
BR112017026561A2 (pt) moduladores alostéricos positivos do receptor muscarínico m2
HK1247919A1 (zh) 毒蕈鹼m1受體正變構調節劑
MA50464A (fr) Amides polycycliques utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1
HUE036698T2 (hu) Mérõeszközök regisztrálása az interneten keresztül
MA51036A (fr) Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
MA51037A (fr) Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
MA50806A (fr) Azacycles substitués utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1
UA36196S (uk) Тяга верхня навісного пристрою транспортного засобу
UA32311S (uk) Тяга верхня навісного пристрою транспортного засобу